{"product_id":"veracyte-business-model-canvas","title":"Veracyte Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock a diagnostics Business Model Canvas: value propositions, customers, revenue drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint of Veracyte with a concise Business Model Canvas that maps value propositions, customer segments, and revenue drivers. See how partnerships and diagnostics scale growth and margin. Ideal for investors and strategists seeking actionable insight. Purchase the full, editable canvas to dive deeper.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic medical centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with leading academic medical centers provide Veracyte access to well-phenotyped cohorts and biobanks to support prospective and retrospective clinical validation for Afirma (thyroid), Percepta (lung) and Envisia (interstitial lung disease). Co-authored, peer-reviewed publications from these sites bolster clinical credibility and guideline inclusion, while IRB-backed studies and joint grants accelerate evidence generation and clinical adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and integrated delivery networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with hospitals and IDNs streamline sample flow, logistics and EHR\/LIS connectivity with major platforms like Epic and Cerner, enabling system-level contracting to embed formularies and testing pathways. IDNs—which control roughly 70% of U.S. hospital bed capacity—use value analyses showing tests can avoid unnecessary procedures, reducing costs and improving clinician adherence and turnaround times often to under 48 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma and companion diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiopharma alliances let Veracyte co-develop companion diagnostics and stratification assays, leveraging clinical-trial samples and outcomes to refine predictive signatures; the global companion diagnostics market was about $9.6 billion in 2023, supporting joint commercialization to expand indications and reimbursement footprints, while shared data enables real-world evidence generation and potential label expansions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers and health technology assessors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngagement with commercial and government payers secures coverage and appropriate reimbursement for Veracyte diagnostics, while health economic studies provide evidence that informs medical policy decisions and payer coverage criteria.\u003c\/p\u003e\n\u003cp\u003eOutcomes-based arrangements can align incentives around reducing unnecessary invasive procedures and associated costs, and early dialogue with HTA bodies improves market access and adoption in new geographies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage agreements\u003c\/li\u003e\n\u003cli\u003eHealth economic evidence\u003c\/li\u003e\n\u003cli\u003eOutcomes-based contracts\u003c\/li\u003e\n\u003cli\u003eEarly HTA engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors and reference labs (ex-US)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational distributors and reference labs extend Veracyte reach into regulated markets, using local licenses and partner networks to enter countries where direct operations would be slow or costly.\u003c\/p\u003e\n\u003cp\u003eLocal entities handle country-specific compliance, logistics, and payer-system navigation, reducing time-to-reimbursement and market access friction.\u003c\/p\u003e\n\u003cp\u003eRigorous tech transfers and QA programs preserve assay fidelity across sites, while co-marketing deals drive adoption without a heavy direct commercial footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory reach via partners\u003c\/li\u003e\n\u003cli\u003eLocal compliance and payer navigation\u003c\/li\u003e\n\u003cli\u003eTech transfer + QA for assay consistency\u003c\/li\u003e\n\u003cli\u003eCo-marketing to scale adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic, IDN and biopharma partnerships accelerate companion Dx, EHR integration and payer access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAcademic centers supply cohorts\/biobanks for validation, producing guideline-supporting publications and IRB studies.\u003c\/p\u003e\n\u003cp\u003eIDN\/hospital partnerships enable EHR\/LIS integration (Epic\/Cerner), system contracting and sample logistics, with IDNs covering ~70% of US beds and TAT often \u0026lt;48 hours.\u003c\/p\u003e\n\u003cp\u003eBiopharma alliances drive companion diagnostics co-development; global companion diagnostics market ~11B USD (2024 est), enabling label expansions and RWE.\u003c\/p\u003e\n\u003cp\u003ePayer and distributor deals secure coverage, outcomes-based contracts and local market access via tech transfer and QA.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic centers\u003c\/td\u003e\n\u003ctd\u003eValidation \u0026amp; publications\u003c\/td\u003e\n\u003ctd\u003eIRB studies, cohorts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDNs\/hospitals\u003c\/td\u003e\n\u003ctd\u003eLogistics \u0026amp; EHR integration\u003c\/td\u003e\n\u003ctd\u003e~70% US beds, TAT \u0026lt;48h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003eCompanion Dx\u003c\/td\u003e\n\u003ctd\u003eMarket ~11B USD (2024 est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas tailored to Veracyte’s diagnostics strategy, covering customer segments, channels, value propositions and revenue streams across the 9 BMC blocks with real-world operational insights and competitive advantages. Ideal for investor presentations, strategic planning and includes linked SWOT analysis to validate opportunities and risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Veracyte’s complex diagnostics strategy into a clean, one-page Business Model Canvas that quickly aligns R\u0026amp;D, commercial, and clinical teams. Shareable and editable for fast collaboration, it saves hours on structuring strategy and clarifies value propositions, revenue streams, and partnerships for boardrooms or investor reviews.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssay R\u0026amp;D and platform optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDiscovery and optimization of gene expression and genomic signatures drive clinical performance, with platform updates in 2024 targeting sensitivity and specificity gains. Analytical validation ensures reproducibility and instrument-agnostic sensitivity across labs. Iterative R\u0026amp;D has reduced turnaround time by up to 30% and per-test costs ~20%. Cross-indication platform work enables leverage across a pipeline of multiple diagnostic areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProspective and retrospective studies underlie Afirma and Percepta clinical validity and utility, supported by 400+ peer-reviewed publications as of 2024. Guideline inclusion follows presentations at major meetings and journals. Health-economics analyses report substantial reductions in diagnostic surgeries and per-patient downstream savings of several thousand dollars. Post-market registries with tens of thousands of cases bolster real-world performance claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA\/CAP laboratory operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVeracyte’s CLIA\/CAP laboratory operations in 2024 maintain high-throughput genomic processing under ISO-aligned quality systems to deliver consistent results. Robust logistics track specimen collection, chain-of-custody and TAT metrics to meet clinical deadlines. Continuous QC\/QA, internal controls and external proficiency testing uphold CLIA and CAP accreditation. Capacity planning aligns staffing and equipment with demand to optimize throughput and service levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarket access and reimbursement activities—coding, coverage, and contracting—create predictable payment pathways for Veracyte tests, while proactive medical policy engagement communicates evidence strength to payers. Dedicated appeals and prior-authorization support reduce provider friction and speed uptake. Pricing strategy balances demonstrated clinical value with access goals to enable margin expansion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ecoding, coverage, contracting\u003c\/li\u003e\n\u003cli\u003emedical policy engagement\u003c\/li\u003e\n\u003cli\u003eappeals \u0026amp; prior-auth support\u003c\/li\u003e\n\u003cli\u003evalue-based pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical education and KOL engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMSLs deliver scientific exchange with specialists and societies, supporting adoption of Veracyte tests across clinics; training programs steer ordering, interpretation, and care pathways, driving clinical utility and repeat use. National and regional conferences showcase peer-reviewed data and case studies; advisory boards (2024: engaged 40+ KOLs) inform product roadmap and unmet needs.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMSL scientific exchanges\u003c\/li\u003e\n\u003cli\u003eTraining on ordering \u0026amp; interpretation\u003c\/li\u003e\n\u003cli\u003eConference data dissemination\u003c\/li\u003e\n\u003cli\u003eAdvisory boards (40+ KOLs in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenomic signatures improve care: \u003cstrong\u003e400+\u003c\/strong\u003e pubs, TAT ~\u003cstrong\u003e30%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery and optimization of genomic signatures drive clinical performance (2024: 400+ publications), with iterative R\u0026amp;D cutting turnaround time ~30% and per-test costs ~20%. CLIA\/CAP lab operations and tens of thousands of registry cases ensure real-world validity; Afirma and Percepta supported by prospective\/retrospective studies. Market-access efforts (coding, coverage, appeals) plus 40+ KOLs in 2024 enable uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAT reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-test cost ↓\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistry cases\u003c\/td\u003e\n\u003ctd\u003etens of thousands\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKOLs engaged\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Veracyte Business Model Canvas, not a mockup, and it reflects the exact content you’ll receive after purchase. When you buy, you’ll get this same professional file—complete and ready to edit, present, or share. Files are delivered in editable Word and Excel formats with all sections included.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56161511145849,"sku":"veracyte-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/veracyte-business-model-canvas.png?v=1762694279","url":"https:\/\/portersfiveforce.com\/products\/veracyte-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}